Paladin Energy reports its highest monthly uranium production since March 2024 and completes the strategic acquisition of Fission Uranium Corp, expanding its footprint in Canada’s uranium sector.
Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.
Xanadu Mines has lodged a comprehensive NI 43-101 technical report for its Kharmagtai Copper-Gold Project, revealing key differences in production and economic outcomes compared to earlier ASX disclosures due to regulatory standards.
Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.